Narrow search
Showing 1 - 10 of 2,399
Cover Image
The impact of pharmaceutical innovation on longevity and medical expenditure in France : 2000 - 2009
Lichtenberg, Frank R. - In: Economics and human biology 13 (2014), pp. 107-127
Persistent link: https://www.econbiz.de/10010386634
Cover Image
Innovation, régulation des prix et politique du médicament
Bureau, Dominique; Scherrer, Sylvie - In: Revue d'économie politique 110 (2000) 4, pp. 513-539
Persistent link: https://www.econbiz.de/10001512648
Cover Image
Innovation im Arzneimittelmarkt
Klauber, Jürgen (ed.); Bausch, Jürgen (contributor);  … - 2000
Persistent link: https://www.econbiz.de/10001486392
Cover Image
Substitutability between drugs, innovation, and fiscal policy in the pharmaceutical industry
Mello-Sampayo, Felipa de; Sousa-Vale, Sofia de; Camoes, … - In: Annals of economics and finance 16 (2015) 2, pp. 273-289
Persistent link: https://www.econbiz.de/10011427811
Cover Image
The impact of R&D cooperations on drug variety offered on the market : evidence from the pharmaceutical industry
Banerjee, Tannista; Siebert, Ralph - 2014
drug development portfolio to avoid wasteful duplication and cannibalizing the sales of the jointly developed drug in R …
Persistent link: https://www.econbiz.de/10010229875
Cover Image
What do patent-based measures tell us about product commercialization? : evidence from the pharmaceutical industry
Wagner, Stefan - 2015
Patent-based measures are frequently used as indicators in empirical research on innovation and technology as well as on firms' strategies and organizational choices to characterize inventions or, more generally, innovative activities and the technological capabilities of organizations. A clear...
Persistent link: https://www.econbiz.de/10010258420
Cover Image
What do patent-based measures tell us about product commercialization? : evidence from the pharmaceutical industry
Wagner, Stefan - 2015
Patent-based measures are frequently used as indicators in empirical research on innovation and technological change. Currently, there is little evidence as to what extent patent-based indicators relate to product market outcomes. Using a unique dataset that links outcomes from product...
Persistent link: https://www.econbiz.de/10010497622
Cover Image
How does basic research improve innovation performance in the world's major pharmaceutical firms?
Leten, Bart; Kelchtermans, Stijn; Belderbos, René - In: Industry and innovation 29 (2022) 3, pp. 396-424
Persistent link: https://www.econbiz.de/10013170079
Cover Image
Paying off the competition : market power and innovation incentives
Li, Xuelin; Lo, Andrew W.; Thakor, Richard T. - 2021 - This Draft: 19 June 2021
How does a firm’s market power in existing products affect its incentives to innovate? We explore this fundamental question using granular project-level and firm-level data from the pharmaceutical industry, focusing on a particular mechanism through which incumbent firms maintain their market...
Persistent link: https://www.econbiz.de/10012818283
Cover Image
Developing a system dynamic model for product life cycle management of generic pharmaceutical products : its relation with open innovation
Mousavi, Atefeh; Mohammadzadeh, Mehdi; Zare, Hossein - In: Journal of open innovation : technology, market, and … 8 (2022) 1, pp. 1-19
“reference mode”, determined the causal loop of the pharmaceuticals phase of PLC based on both an in-depth literature review and …’ marketing and R and D activities can raise sales by more than 50% in the decline stage of the PLC. The product life cycle can … give generic manufacturers more insights into the processes leading to declining sales of their products. PLC may help to …
Persistent link: https://www.econbiz.de/10012801597